Retinopathy in diabetes

Advances in Experimental Medicine and Biology

Volumn 771, Issue , 2013, Pages 88-106

  Tarr, Joanna M ^a   Kaul, Kirti ^a   Wolanska, Katarzyna ^a   Kohner, Eva M ^a   Chibber, Rakesh ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AFLIBERCEPT; ALDOSE REDUCTASE INHIBITOR; ARI 809; BEVACIZUMAB; CANDESARTAN HEXETIL; CARBONATE DEHYDRATASE INHIBITOR; CORTICOSTEROID; DEXAMETHASONE; EFALIZUMAB; ERYTHROPOIETIN; FENOFIBRATE; FLUOCINOLONE ACETONIDE; HYALURONIDASE; INFLIXIMAB; LIFITEGRAST; PEGAPTANIB; RANIBIZUMAB; RUBOXISTAURIN; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ARTICLE; BLINDNESS; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG MEGADOSE; EPIDEMIC; HUMAN; INCIDENCE; NONHUMAN; PATHOGENESIS; PREVALENCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; RETINA; REVIEW; RISK FACTOR;

DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; HUMANS; INCIDENCE; PREVALENCE; RETINA; RISK FACTORS;

MLCS; MLOWN;

EID: 84874523774     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-1-4614-5441-0_10     Document Type: Article

References (116)

1. Wang Y, Fawzi A, Tan G et al. Retinal blood flow detection in diabetic patien ts by Doppler Fourier domain optical coherence tomography. Opt Express 2009; 17(5):4061-4073.
2. Abramoff MD, Niemeijer M, Russell SR. Automated detection of diabetic retinop athy: barriers to translation into clinical practice. Expert Rev Med Devices 2010; 7(2):287-296.
3. Wilkinson CP, Ferris FL, 3rd, Klein RE et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003; 110(9):1677-1682.
4. Patel V, Rassam S, Newsom R et al. Retinal blood flow in diabetic retinopathy. BMJ 1992; 305(6855):678-683.
5. Cogan DG, Toussaint D, Kuwabara T. Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol 1961; 66:366-378.
6. Addison DJ, Garner A, Ashton N. Degeneration of intramural pericytes in diabetic retinopathy. Br Med J 1970; 1(5691):264-266.
7. Sato Y, Kamata A, Matsui M. Clinical study of venous abnormalities in diabetic retinopathy. Jpn J Ophthalmol 1993; 37(2):136-142.
8. McLeod D, Marshall J, Kohner EM et al. The role of axoplasmic transport in the pathogenesis of retinal cotton-wool spots. Br J Ophthalmol 1977; 61(3):177-191.
9. Klein R, Klein BE, Moss SE et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102(4):527-532.
10. Klein R, Klein BE, Moss SE et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102(4):520-526.
11. Bresnick GH, De Venecia G, Myers FL et al. Retinal ischemia in diabetic retinopathy. Arch Ophthalmol 1975; 93(12):1300-1310.
12. Fong DS, Aiello LP, Ferris FL 3rd et al. Diabetic retinopathy. Diabetes Care 2004; 27(10):2540-2553.
13. Malone JI, Morrison AD, Pavan PR et al. Prevalence and significance of retinopathy in subjects with type 1 diabetes of less than 5 years' duration screened for the diabetes control and complications trial. Diabetes Care 2001; 24(3):522-526.
14. Roy MS, Klein R, O'Colmain BJ et al. The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States. Arch Ophthalmol 2004; 122(4):546-551.
15. Klein R, Klein BE, Moss SE et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995; 102(1):7-16.
16. Klein BE, Moss SE, Klein R. Is menarche associated with diabetic retinopathy? Diabetes Care 1990; 13(10):1034-1038.
17. Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990; 13(1):34-40.
18. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care 2000; 23(8): 1084-1091.
19. Warpeha KM, Chakravarthy U. Molecular genetics of microv asculardisease in diabetic retinopathy. Eye (Lond) 2003; 17(3):305-311.
20. Patel S, Chen H, Tinkham NH et al. Genetic susceptibility of diabetic retinopathy. Curr Diab Rep 2008; 8(4):257-262.
21. Kohner EM. The evolution and natural history of diabeticretinopathy. Int Ophthalmol Clin 1978; 18(4):1-16.
22. Kohner EM, Sieightholm M. Does microaneurysm count reflect severity of early diabetic retinopathy? Ophthalmology 1986; 93(5):586-589.
23. Frank RN. On the pathogenesis of diabetic retinopathy. Ophthalmology 1984; 91(6):626-634.
24. Stitt AW, Gardiner TA, Archer DB. Histological and ultrastructural investigation of retinal microaneurysm development in diabetic patients. Br J Ophthalmol 1995; 79(4):362-367.
25. Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996; 97(12):2883-2890.
26. Hammes HP, Lin J, Renner G et al. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes 2002; 51(10):3107-3112.
27. Orlidge A, D'Amore PA. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J Cell Biol 1987; 105(3):1455-1462.
28. Hellstedt T, Immonen I. Disappearance and formation rates of microaneurysms in early diabetic retinopathy. Br J Ophthalmol 1996; 80(2):135-139.
29. Ashton N. Studies of the retinal capillaries in relation to diabetic and other retinopathies. Br J Ophthalmol 1963; 47:521-538.
30. Kohner EM, Henkind P. Correlation of fluorescein angiogram and retinal digest in diabetic retinopathy. Am J Ophthalmol 1970; 69(3):403-414.
31. Ljubimov AV, Burgeson RE, Butkowski RJ et al. Basement membrane abnormalities in human eyes with diabetic retinopathy. J Histochem Cytochem 1996; 44(12):1469-1479.
32. Form DM, Pratt BM, Madri JA. Endothelial cell proliferation during angiogenesis. In vitro modulation by basement membrane components. Lab Invest 1986; 55(5):521-530.
33. Ingber DE, Folkman J. How does extracellular matrix control capillary morphogenesis? Cell 1989; 58(5):803-805.
34. Folkman J, Klagsbrun M, Sasse J et al. A heparin-binding angiogenic protein-basic fibroblast growth factor-is stored within basement membrane. Am J Pathol 1988; 130(2):393-400.
35. Hanneken A, de Juan E, Jr, Lutty GA et al. Altered distribution of basic fibroblast growth factor in diabetic retinopathy. Arch Ophthalmol 1991; 109(7): 1005-1011.
36. Vigny M, Ollier-Hartmann MP, Lavigne M et al. Specific binding of basic fibroblast growth factor to basement membrane-like structures and to purified heparan sulfate proteoglycan of the EHS tumor. J Cell Physiol 1988; 137(2):321-328.
37. Roy S, Ha J, Trudeau K et al. Vascular basement membrane thickening in diabetic retinopathy. Curr Eye Res 2010; 35(12):1045-1056.
38. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mell itus. N Engl J Med 1993; 329:977-986.
39. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131):837-853.
40. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 2003; 46(Suppl 1):M9-16.
41. Gabbay KH. Hyperglycemia, polyol metabolism and complications of diabetes mellitus. Annu Rev Med 1975; 26:521-536.
42. Obrosova GI, Kador PF. Aldose reductase/polyol inhibitors for diabetic retinopathy. Curr Pharm Biotechnol 2011; 12(3):373-385.
43. Amano S, Yamagishi S, Koda Y et al. Polymorphisms of sorbitol dehydrogenase (SDH) gene and susceptibility to diabetic retinopathy. Med Hypotheses 2003; 60(4):550-551.
44. Comer GM, Ciulla TA. Pharmacotherapy for diabetic retinopathy. Curr Opin Ophthalmol 2004; 15(6):508-518.
45. Ishida S, Usui T, Yamashiro K et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003; 44(5):2155-2162.
46. Zhang XL, Wen L, Chen YJ et al. Vascular endothelial growth factor up-regulates the expression of intracellular adhesion molecule-1 in retinal endothelial cells via reactive oxygen species, but not nitric oxide. Chin Med J (Engl) 2009; 122(3):338-343.
47. Nagpala PG, Malik AB, Vuong PT et al. Protein kinase C beta 1 overexpression augments phorbol ester-induced increase in endothelial permeability. J Cell Physiol 1996; 166(2):249-255
48. Geraldes, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010; 106:1319-1331.
49. Sjolie AK, Chaturvedi N. The retinal renin-angiotensin system: implicatio ns for therapy in diabetic retinopathy. Journal of human hypertension 2002; 16(Suppl 3):S42-46.
50. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.
51. Stitt AW. AGEs and diabetic retinopathy. Invest Ophthalmol Vis Sci 2010; 51(10):4867-4874.
52. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107(9):1058-1070.
53. Pemp B, Polska E, Garhofer G et al. Retinal blood flow in type 1 diabetic patients with no or mild diabetic retinopathy during euglycemic clamp. Diabetes Care 2010; 33(9):2038-2042.
54. Burgansky-Eliash Z, Nelson DA, Bar-Tal OP et al. Reduced retinal blood flow velocity in diabetic retinopathy. Retina 2010; 30(5):765-773.
55. Bursell SE, Clermont AC, Kinsley BT et al. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci 1996; 37(5):886-897.
56. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol 2002; 86(4):363-365.
57. Schroder S, Palinski W, Schmid-Schonbein GW. Activated monocytes and granulocytes, capillary nonperfusion and neovascularization in diabetic retinopathy. Am J Pathol 1991; 139(1):81-100.
58. Lutty GA, Cao J, McLeod DS. Relationship of polymorphonuclear leukocytes to capillary dropout in the human diabetic choroid. Am J Pathol 1997; 151(3):707-714.
59. Chibber R, Ben-Mahmud BM, Coppini D et al. Activity of the glycosylating enzyme, core 2GlcNAc (beta 1,6) transferase, is higher in polymorphonuclear leukocytes from diabetic patients compared with age-matched control subjects: relevance to capillary occlusion in diabetic retinopathy. Diabetes 2000; 49(10):1724-1730.
60. Chibber R, Ben-Mahmud BM, Mann GE et al. Protein kinase C beta2-dependent phosphorylation of core 2 GlcNAc-T promotes leukocyte-endothelial cell adhesion: a mechanism underlying capillary occlusion in diabetic retinopathy. Diabetes 2003; 52(6):1519-1527.
61. Chibber R, Ben-Mahmud BM, Chibber S et al. Leukocytes in diabetic retinopathy. Curr Diabetes Rev 2007; 3(1):3-14.
62. Niki T, Muraoka K, Shimizu K. Distribution of capillary nonperfusion in early-stage diabetic retinopathy. Ophthalmology 1984; 91(12):1431-1439.
63. Shimizu K, Muraoka K. Diabetic retinopathy. Is it a maculopathy? A super-wide fluorescein angiographic evaluation. Dev Ophthalmol 1981; 2:235-242.
64. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-854.
65. White NH, Sun W, Cleary PA et al. Prolonged effect of intensive therapy on the risk of retinopathy complications inpatients with type I diabetesmellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 2008; 126(12):1707-1715.
66. White NH, Sun W, Cleary PA et al. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC:comparison of adults and adolescents. Diabetes 2010; 59(5):1244-1253.
67. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998; 116(7):874-886.
68. Suzuma I, Hata Y, Clermont A et al. Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension. Diabetes 2001; 50(2):444-454.
69. Gallego PH, Craig ME, Hing S et al. Role of blood pressure in development of early retinopathy in adolescents with type 1 diabetes: prospective cohort study. BMJ 2008; 337. a918.
70. Klein R, Knudtson MD, Lee KE et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009; 116(3):497-503.
71. Chew EY, Klein ML, Ferris FL 3rd et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996; 114(9):1079-1084.
72. van Leiden HA, Dekker JM, Moll AC et al. Blood pressure, lipids and obesity are associatedwith retinopathy: the hoorn study. Diabetes Care 2002; 25(8):1320-1325.
73. Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370(9600):1687-1697.
74. Gordon B, Chang S, Kavanagh M et al. The effects of lipid lowering on diabetic retinopathy. Am J Ophthalmol 1991; 112(4):385-391.
75. Gupta A, Gupta V, Thapar S et al. Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema. Am J Ophthalmol 2004; 137(4):675-682.
76. Sen K, Misra A, Kumar A et al. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res Clin Pract 2002; 56(1):1-11.
77. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of diabetic retinopathy study findings. Ophth almology 1978; 85(1):82-106.
78. Treatment techniques and clinical guidelines for photoco agulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1987; 94(7):761-774.
79. Sivaprasad S, Elagouz M, McHugh D et al. Micropulsed diode laser therapy: evolution and clinical applications. Surv Ophthalmol 2010; 55(6):516-530.
80. Muqit MM, Gray JC, Marcellino GR et al. Barely visible 10-millisecond pascal laser photocoagulation for diabetic macular edema: observations of clinical effect and burn localization. Am J Ophthalmol 2010; 149(6):979-986 e972.
81. Casson RJ, Raymond G, Newland HS et al. A pilot, prospective randomised clinical trial of a new nanopulse retinal laser versus convential photocoagulation for the treatment of diabetic macular edema. In: ARVO; Fort Lauderdale, 2010.
82. Spraul CW, Grossniklaus HE. Vitreous hemorrhage. Surv Ophthalmol 1997; 42(1):3-39.
83. Early vitrectomy for severe vitreous hemorrh age in diabetic retinopathy. Four-year results of arandomized trial: Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophth almol 1990; 108(7):958-964.
84. Obrosova IG, Minchenko AG, Vasupuram R et al. Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes 2003; 52(3):864-871.
85. Oates PJ, Mylari BL. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin Investig Drugs 1999; 8(12):2095-2119.
86. Sun W, Oates PJ, Coutcher JB et al. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retina labnormalities in experimental diabetic retinopathy. Diabetes 2006;55(10):2757-2762.
87. Ishii H, Jirousek MR, Koya D et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272(5262):728-731.
88. Aiello LP, Bursell SE, Clermont A et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoforrn-selective inhibitor. Diabetes 1997; 46(9):1473-1480.
89. Danis RP, Bingaman DP, Jirousek M et al. Inhibition of intraocular neovascu larization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci 1998; 39(1): 171-179.
90. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinop athy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005; 54(7):2188-2197.
91. Davis MD, Sheetz MJ, Aiello LP et al. PKC-DRS2 Study Group. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest Ophthalmol Vis Sci. 2009; 50(1):1-4.
92. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DM ES clinical trial. Arch Ophthalmol 2007; 125(3):318-324.
93. Cunningham ET Jr, Adamis AP, Altaweel M et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112(10):1747-1757.
94. Adamis AP, Altaweel M, Bressler NM et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006; 113(1):23-28.
95. Chun OW, Heier JS, Topping TM et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006; 113(10):1706-1712.
96. Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113(10): 1695 e1691-1615.
97. Jorge R, Costa RA, Calucci D et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE study). Retina 2006; 26(9):1006-1013.
98. Zhang J, Hu LM, Xu G et al. Anti-VEGF effects of intravitreal erythropoietin in early diabetic retinopathy. Front Biosci (Elite Ed). 2010; 1;2:912-27.
99. Nguyen QD, Shah SM, Browning DJ et al. A phase I study of intravi treal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 2009; 116(11):2141-2148 e2141.
100. Do DV, Nguyen QD, Shah SM et al. An exploratory study of the safety, tolerability and bioactivity of a single intravi treal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macularoedema. Br J Ophthalmol 2009; 93(2):144-149
101. Saint-Geniez M, Maharaj AS, Walshe TE et al. Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photorecep tors. PLoS One. 2008; 3(11):e3554.
102. Chaturvedi N, Porta M, Klein R et al. Effect of cande sartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372(9647): 1394-1402.
103. Sjolie AK, Klein R, Porta M et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): arandomised placebo-controlled trial. Lancet 2008;372(9647):1385-1393.
104. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98(5 Suppl):757-765.
105. Brooks HL, Jr, Caballero S, Jr, Newell CK et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol 2004; 122(12):1801-1807.
106. Gillies MC, Sutter FK, Simpson JM et al. Intravitreal triamcinolone for refractory diabeticmacular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006; 113(9):1533-1538.
107. Jaffe GJ, Martin D, Callanan D et al. Fluocinolone acetonide implant (Retisert) for noninfe ctious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006; 113(6):1020-1027.
108. Haller JA, Kuppermann BD, Blumenkranz MS et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010; 128(3):289-296.
109. Schwartz SG, Flynn HW, Jr. Fluocinolone acetonide implantable device for diabetic retinopathy. Curr Pharm Biotechnol 2011; 12(3):347-351.
110. Sfikakis PP, Grigoropoulos V, Emfietzoglou I et al. Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study. Diabetes Care 2010; 33(7):1523-1528.
111. Wang J, Ibrahim M, Turkcuoglu P et al. Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema. Ocul lmmunol Inflamm 2010; 18(5):395-398.
112. Rao VR, Prescott E, Shelke NB et al. Delivery of SAR 1118 to the retin a via ophthalmic drops and its effectiveness in a rat streptozo toc in (STZ) model of diabetic retinopathy (DR). Invest Ophth almol Vis Sci 2010; 51(10):5198-5204.
113. Weiwei Z, Hu R. Targeting carbonic anhydrase to treat diabetic retinopathy: emerging evidences and encouraging results. Biochem Biophys Res Commun 2009; 390(3):368-371.
114. Trese MT. Enzymatic-assisted vitrectomy. Eye (Lond) 2002; 16(4):365-368.
115. Gandorfer A. Enzymatic vitreous disruption. Eye (Lond) 2008; 22(10):1273-1277.
116. Gremizzi C, Vergani A, Paloschi V et al. Impact of pancreas tran splantation on type 1 diabetes-related complications. curr Opin Organ Transplant 2010; 15(1): 119-123.